Lung Bacteriobiota and Influenza Mortality

University of Bordeaux64 enrolled

Overview

Influenza is a potentially lethal disease still responsible for thousands excess deaths both in Europe and the United States. Despite the use of neuraminidase inhibitors, its treatment is mostly based on symptomatic care. Lung microbiota has been shown to be involved in the immunity against influenza and is correlated with lung inflammation in numerous chronic respiratory diseases. We therefore aim to analyse the correlation between lung bacteriobiota and influenza ICU mortality

Influenza is a viral disease which is still responsible for thousands of excess deaths par year both in Europe and in the US. Despite the use of neuraminidase inhibitors, its treatment is mostly based on symptomatic care. As lung microbiota is correlated with lung inflammation in numerous chronic respiratory diseases, we hypothesize that lung microbiota would be correlated with influenza outcomes. In a pilot study, we found that lung bacteriobiota but not mycobiota is associated with influenza ICU mortality. We therefore aim to confirm this correlation between lung bacteriobiota and influenza mortality.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Influenza Critical Illness

Interventions

influenza screeningDIAGNOSTIC_TEST

positive influenza screening

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient above 18 year-old admitted to intensive care unit * Influenza diagnosis by PCR or rapid diagnostic test Exclusion Criteria: * Guardianship or curatorship * Prisoners * No health insurance * No legal representative

Locations (3)

Medical intensive care unit, Pellegrin hospital

Bordeaux, New Aquitaine, France

Intensive care unit, CH Robert Boulin

Libourne, France

Intensive care unit, CH Francois Mitterrand

Pau, France

Outcomes

Primary Outcomes

Lung bacteriobiota and ICU mortality

Comparison of lung bacteriobiota alpha diversity between influenza ICU survivors and non-survivors

Time frame: at admission

Secondary Outcomes

Lung bacteriobiota and ICU mortality

Analysis of lung bacteriobiota beta diversity between influenza ICU survivors and non-survivors

Time frame: at admission

Lung bacteriobiota and 7-day mortality

Analysis of lung bacteriobiota beta diversity between influenza 7-day survivors and non-survivors

Time frame: at admission

Bacteria and ICU mortality

Association of bacteria with influenza ICU mortality by LefSe method

Time frame: at admission

Bacteria and 7-day mortality

Association of bacteria with influenza 7-day mortality by LefSe method

Time frame: at admission

ICU mortality based on Shannon index

Comparison of ICU mortality based on a threshold of 1.79 for Shannon Index

Time frame: at admission

Lung bacteriobiota and 7-day mortality

Comparison of lung bacteriobiota alpha diversity between influenza 7-day survivors and non-survivors

Time frame: at admission

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.